



GEORGIA Life Sciences 2023 SUMMIT

Presented by

GEORGIA BIO™

The Life Sciences Partnership

November 1, 2023 | Sandy Springs Performing Arts Center

#GaBioSummit

SPEAKERS

Speaker Biographies

Patients, Policy & Politics: How Life Sciences is a Key Priority for Georgia & Patients - 10:00 -11:00 AM

THE HONORABLE MAYOR RUSTY PAUL

Elected mayor in November 2013, Russell K. (Rusty) Paul brings more than 40 years of federal, state and local public policy and public administration experience to the job. He is currently serving his third term.

Mr. Paul was elected to the founding city council for Sandy Springs in November 2005 and served one term. He chaired the city's charter review commission and the Sandy Springs Development Authority.

He was confirmed unanimously by the U.S. Senate as Assistant Secretary for Congressional and Intergovernmental Relations in the first Bush Administration under Secretary Jack Kemp. Secretary Kemp also appointed him acting Assistant Secretary of Community Planning and Development and tapped him to oversee the department's disaster response to Hurricane Hugo and the 1989 San Francisco earthquake.

He received the Secretary's Golden Eagle Award, the highest honor a cabinet officer can bestow.

Besides his stints in federal government, Mr. Paul is a former Georgia State Senator and also served on the Stone Mountain City Council and served three terms on the Georgia Municipal Association board of directors.

In 1995, he was elected chairman of the Georgia Republican Party and served on the Republican National Committee, where RNC Chair Jim Nicholson appointed him to chair the State Chairman's Advisory Committee.

He is a past chairman of the Sandy Springs/Perimeter Center Chamber of Commerce and a member of Sandy Springs Rotary. He and his wife, Jan, are parents of five adult children and attend Holy Innocents Episcopal Church.

STEVE DAMON, CEO, MICRON BIOMEDICAL, INC.; GEORGIA BIO CHAIR

Mr. Damon has over 30 years of experience with various business roles in the medical device and pharmaceutical industries.

Steven most recently served as Vice President, Business and Commercial Development for Femasys Inc. where he attained banking and investor relationships that led to ~ \$60M in financing, secured strategic partnerships, led sales and marketing, developed the business plan and supported the clinical development for FemBloc the company's key asset.

Steven founded 4P Therapeutics in 2011 serving as the President and CEO. He sold to Nutriband Inc. in 2018. 4P Therapeutics had established partnerships with Astra Zeneca, Pain Therapeutics, Kimberly-Clark, Halyard Health and many others involved in the research and

development of novel transdermal products. Steven was the principle inventor of an abuse deterrent technology for transdermal delivery of narcotics. Nutriband continues to develop the technology and related products.

Before founding 4P Therapeutics, Steven led partnership and funding efforts at Altea Therapeutics as the company's Senior Vice President of Business and Corporate Development.

Prior to joining Altea Therapeutics, Steven Damon was a member of the executive management team at Durect Corporation in Cupertino, Ca, where he served as Executive Director for Business and Corporate Development.

Steven was also the founder and President of Absorbable Polymers International.

He was a senior management member of the Professional Health Care team at Kimberly-Clark Corporation, with lead responsibilities for commercial development of the healthcare business in Europe and lead responsibilities for a number of major bolt on acquisitions.

Steven serves on the Board of Directors for Temple Therapeutics, Nutriband Inc., Micron and Georgia BIO. He also serves as a mentor for the Georgia Tech and Emory TiGER program. Steven has maintained Business and Corporate Development consultant/advisory roles throughout his career including supporting the sale of Map Pharmaceuticals to Allergan. Steven is a minor investor in several early stage companies.

TIMOTHY L. DENNING, PH.D., PRESIDENT & CEO, GEORGIA RESEARCH ALLIANCE

Dr. Tim Denning serves as the fourth President and CEO of Georgia Research Alliance. Prior to this, Tim served as vice president for research and economic development at Georgia State University and as a Distinguished University Professor in the university's Institute for Biomedical Sciences (IBMS), where he was previously associate director and director of academic programs.

He earned a Ph.D. in microbiology and immunology at the University of Texas Medical Branch, and did postdoctoral training at the La Jolla Institute and the Emory Vaccine Center. Before joining Georgia State in 2013, he was an assistant professor in the Department of Pediatrics and the Department of Pathology and Laboratory Medicine at Emory University. Dr. Denning's research focuses on inflammatory bowel diseases including Crohn's disease and ulcerative colitis, and has been supported throughout his career by the NIH and the Crohn's and Colitis Foundation.

Dr. Denning served in numerous leadership roles at Georgia State including as chair of the Institutional Biosafety Committee and vice chair of the Institutional Animal Care and Use Committee. Additionally, he spearheaded the development of a new Ph.D. program in Translational Biomedical Sciences, a Master of Interdisciplinary Studies with a concentration in Biomedical Enterprise and a Bachelor of Interdisciplinary Studies with a concentration in Biomedical Science and Enterprise.

Dr. Denning served as vice president for research and economic development at Georgia State since 2020.

DOROTHY LEONE-GLASSER, RN, HHC, EXECUTIVE DIRECTOR, ADVOCATES FOR RESPONSIBLE CARE

Dorothy Leone-Glasser, RN, HHC, has lived with systemic lupus for over forty-five years. As a result, she has overcome two forms of cancer, disabling arthritis, kidney failure, seizures, coma, heart attack, and strokes. During this time, she graduated from a wheelchair to crutches to ultimately walking with her own two feet. Between the ages of 20 and 37, Dorothy received three death sentences imposed by her doctors. From receiving the National Arthritis Foundation Hero Award to her advocacy initiatives, she is alive and paving the way to the future of wellness and equitable health care delivery as Executive Director of the Advocates for Responsible Care (ARxC), a non-profit wellness and advocacy organization. ARxC's mission is to help empower individuals to achieve their maximum wellness with a strong voice as health advocates effectively reducing cultural incompetency and health care delivery disparities.

As Dorothy drove her wheelchair, she also drove her career. Dorothy's philosophy, "Illness lives in the mind, plays out in the body, and comes to a place of peace in the spirit where wellness survives" was the compelling energy behind her success. Empowering others with her personal philosophy and raising a strong voice of advocacy, Dorothy has taught countless others how to "live wise and live well" and raise their voices.

She was a thirty-eight-year member of the Board of Directors at the Arthritis Foundation, GA (AF), serving as the GA Advocacy Chair on the Leadership Council for the SE Region. Dorothy provides advocacy consulting to numerous organizations, societies and patient groups. She facilitates an ongoing patient group ARxC STARS that empowers its members to promote wellness and prevention practices along with being active healthcare advocates. She has published countless materials educating patients about wellness power and advocacy. Dorothy is frequently seen and heard on TV, radio, and print media and testifies before congressional committees and local government Boards on health care advocacy issues. She has been recognized by the National Association of Professional Women as 'Woman of the Year 2012'. Dorothy received the 2013 "Latino Health Excellence Award" from the Hispanic Health Coalition of Georgia and in 2016 received the Arthritis Foundation GA "Outstanding Service Award" for her advocacy work. In 2020, ARxC received the Atlanta Business Chronicle Community Outreach Health Care Hero Award for distributing PPE, meals, laptops and supplies to first responders, Georgia hospitals and communities in need. In May 2022, Dorothy and ARxC received the Center for Global Health Innovation (GA Bio) Golden Helix Community Award.

Dorothy was asked to speak with President George W. Bush to a crowd of 4,200 citizens, legislators, and community and civic leaders at the Atlanta Civic Center, in Atlanta. They discussed Dorothy's experiences and insights educating people on the new Medicare benefits and enrollment for Part D prescription drug coverage.

The Advocates for Responsible Care have always advocated for full access to medications and treatments with an emphasis on reducing health disparities. In 2011 ARxC, along with Georgia Bio, took the lead to organize the Rx in Reach GA Coalition (Rx in Reach GA) consisting of 45 health and physician organizations who promote legislative policies that ensure patient protections and affordable access to life-saving prescription drugs and treatments. She has led this coalition to passing Biosimilar legislation, Step Therapy Reform and PBM Oversight, Physician Prior Authorization Transparency and Vaccine Authorization legislation in Georgia and Mental Health Parity. Currently, Rx in Reach is working to pass prescription drug rebates to

patients at point of sale. ARxC has partnered with Compassionate Atlanta to create the Georgia Coalition for Safe Communities (GCSC); believing gun violence is a public health crisis and advocates for federal, state and private funding for gun violence research that measures its impact on the health of our communities. The GCSC lead the support and successful passing of the Hate Crimes Bill and Citizen's Arrest Repeal in Georgia. GCSC, as a member of Northwell Health Gun Violence Prevention Collaborative, informs, educates and mobilizes Georgians to promote common sense gun policies that ensure safety and prevent violence.

As the legal representative and medical director of the patients of the Grady Dialysis Crisis, ARxC led the negotiations for long-term treatments and continues to work toward a permanent solution to their care. In December 2010 Dorothy received the Mundo Hispanico Award, *Amigo de los Hispanos*, for her work in advocating for dialysis patients who were in jeopardy of dying without dialysis treatment. ARxC is a partner of the Coalition for Responsible Kidney Care, a group of concerned medical professionals working to change CMS rule to include uninsured and undocumented status patients of ESRD, to ensure their dialysis treatment.

In 2021, she accepted the position of Chair of the Center for Global Health Innovation (CGHI) formerly GA Bio, Patient Advocacy Alliance, leading the collaboration and partnership of patient advocacy community and life sciences leaders creating opportunities for expanding access to our treatment landscape while sharing strategies and actions on critical health policy issues.

ZACHARY POSS, DIRECTOR - STATE ADVOCACY, PhRMA

Zach Poss is Director of State Policy for PhRMA. In his tenure, he has worked with states on a wide-range of health policy issues throughout the Southeast and Midwest and leads PhRMA's state policy team on PBM issues. Prior to working at PhRMA, Zach interned with Senator Lamar Alexander, then chair of the Senate HELP Committee. Zach is a proud graduate of the American University, where he earned his Bachelor of Arts in Political Science and George Washington University, where he earned his Master of Public Policy.

THE HONORABLE REP. DEBORAH SILCOX (R)

Deborah Silcox is an attorney, a mother, and a community activist. She grew up in Sandy Springs and graduated from Riverwood High School. She subsequently earned her Bachelor of Arts degree from the University of Georgia and went on to finish her law degree from Emory University School of Law. Deborah practiced law for ten years and gave up partnership to raise her family. During this time, she served on the boards of The Junior League of Atlanta, The Atlanta Speech School, Hands on Georgia, and The Chastain Park Conservancy. Governor Sonny Perdue appointed her to serve on the Department of Human Resources Board as well as The Governor's Commission for Volunteerism and Service. Governor Nathan Deal chose Deborah as Chairman of The Governor's Commission for Volunteerism and Service. The people of State House District 52 elected Deborah as their State Representative where she served from 2016-2020. In 2017 the Georgia Ophthalmology Society named Deborah the "Legislator of the Year". She also earned a Health Policy Certificate in 2017 from the Georgia State Health Policy Center. For her work in the 2018 legislative session, the Georgia Municipal Association named Deborah a "Champion of Georgia's Cities". Also in 2018, Deborah received the 1849

“Friend of Medicine Award” from the Medical Association of Georgia for her legislative work on behalf of physicians and their patients. In September of 2019, Deborah travelled to Japan to represent Georgia on an economic development trip as guest of the Japanese government. Later in 2019, Speaker David Ralston appointed Deborah Chairman of the House MARTOC Committee that oversees MARTA and named her a Deputy Whip. In January of 2020 "Engineering Georgia" Magazine highlighted Deborah as one the Top 100 Most Influential Women in Georgia and was also chosen as a "Lawyer of Distinction." While in the Georgia House, she served on the Judiciary, Health and Human Services, Non-Civil Judiciary, Code Revision, Education Appropriations, and State Planning and Community Affairs Committees.

Following the 2020 census, Deborah was reelected to The Georgia House of Representatives in 2022 to represent House District 53. She is the only Republican Representative inside of I-285. She was renamed Chairman of the MARTOC Committee in the House as well as Vice Chairman of the Non-Civil Judiciary Committee by Speaker Jon Burns. She also serves on the Judiciary, Public Health and Urban Affairs Committees in the House.

In her community, Deborah currently serves on the Board of Trustees for The Richard B. Russell Library at The University of Georgia, The Georgia Commission on the Holocaust, the Advisory Board for The Chastain Park Conservancy, the Advisory Council for The Sandy Springs Conservancy, and is an active member of The Sandy Springs Society.

For over thirty-three years, Deborah has been married to Dr. Hal Silcox III. She and her husband are members of Peachtree Presbyterian Church. Deborah and Hal have two grown children- Elizabeth and Hal IV.

JENEE' BURKE, DIRECTOR, STATE GOVERNMENT RELATIONS & PUBLIC AFFAIRS, UCB

Jenee' Burke is UCB's Director of Government Relations and Public Affairs for the Southeast Region encompassing Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, South Carolina, and Tennessee. In her role, Burke focuses on legislative and policy initiatives to provide positive outcomes for patients with Epilepsy, Parkinson's Disease, Arthritis and various Rare Diseases. Prior to joining UCB in 2018, she was the Principle Consultant for J. Burke Strategies, LLC representing numerous clients including Airbnb, Nissan, the Georgia Association of Genetics Counselors, the Solar Industry and numerous others. In addition to her lobbying experience, Jenee' served as a communications and policy analyst for the Georgia House of Representatives from 2005 until 2013.

Patients, Policy & Politics: Putting the Tech in Bio/MedTech: The Intersection of Software and Science - 11:00 AM - 12:00 PM

MICHEL VAN MUSSCHENBROEK, FIELD MARKETING MANAGER, MILLIPORESIGMA

Michel van Musschenbroek (pronounced – Michelle van mush-in-brook) has worked for MilliporeSigma for more than 30 years. He has supported the pharma biotech, food and beverage industries in various roles from Technical Services, Inside and Field Sales to his current position of Field Marketing. Acting as a liaison, he brings insights of the industry to product managers and in turn help introduce new products.

He holds certifications from the University of North Georgia and the University of Tennessee. In his personal time Michel is coach for middle and high school athletes along with being one of the certified coach trainers for the Georgia Cycling Association.

PATRICIA OBERMAIER, CHIEF GROWTH OFFICER, GLOBAL HEALTH AND LIFE SCIENCES, MICROSOFT

A seasoned business executive, board member and industry award recipient, Patty drives business transformations through market opportunity capture. She leads emerging growth worldwide for Microsoft's \$12B health and life sciences business. In this role, she identifies emerging opportunities and leads Microsoft's efforts to mobilize and activate commercial resources to capture market share. Prior to this role, Patty led Microsoft's US Health and Life Sciences business unit with P&L responsibility for enterprise customers across providers, payers, and life sciences. As a pragmatic strategist and execution leader, she doubled the business from \$3B to \$6B while addressing critical industry needs during the Covid19 pandemic and recent global economic challenges.

Known for thinking differently and seeking innovation, Patty has a strong track record of developing high-performing, diverse organizations that deliver exceptional business results. She and her team of industry, sales and technology professionals collaborate with Microsoft customers and partners to help them overcome challenges with generative AI, Microsoft Cloud, modern work platforms and other trusted solutions.

Prior to joining Microsoft in July 2019, Patty founded and was CEO of Resigility, a strategic advisory and information management services firm where she continues to serve as board chair. She consulted with c-level clients to develop digital strategies to build organizational resilience, agility and performance by modernizing information technology, analytics and data capabilities.

Patty previously held executive roles at Iqvia and Unisys with P&L and delivery responsibilities for analytics and technology solutions to healthcare payers, providers and government agencies. She serves on numerous boards including Applied Information Sciences, Greater Washington Partnership, Northern Virginia Technology Council, and The Women's Center.

Passionate about using technology to solve human challenges and cultivating leadership skills in future generations, Patty is an executive mentor and board member of the Global Good Fund, and volunteers for the Girl Scouts, Boy Scouts, and Girls Excelling in Math and Science.

Patty holds a bachelor's degree in biology from the Massachusetts Institute of Technology and earned her MBA from the Darden School at the University of Virginia. She and her family reside in Oakton, Virginia, and are committed to community service, with her three children being featured speakers at Youth Bike Summits and spotlighted on Nickelodeon's Worldwide Day of Play, NPR and Salud America!

JOSEPH (ROBBY) ROBERTSON, PRODUCT AND TECHNOLOGY LEAD, US NEUROLOGY, UCB

Robby serves as the Product and Technology Lead for US Insights to Impact Team at UCB. He has been leading work in AI-based technology and has deep experience in Software Engineering and Data Science applied to the healthcare space, utilizing healthcare-related real-world evidence (EMR/HR), commercial, and customer behavior data. Robby has been with UCB for the last 8 years. He has done extensive research in collaboration with leading academic institutions for predicting disease severity progression of Neurological diseases like epilepsy so that patients can be helped with early intervention with appropriate therapy. He has conducted pioneering work in advancing some of the research into a regulated Software As a Medical Device (SaMD) product in UCB's exploration in this space.

Currently, he is leading efforts to mature UCB's understanding of the patient journey and the obstacles that patients and physicians face in finding the right diagnosis and treatment approach, particularly in rare or otherwise hard-to-diagnose diseases.

Prior to joining UCB, Robby served as Chief Data Scientist at Illuminate360; was Cofounder & Head of Insights at Saygent; and Director for Advanced Analytics Research at Liveperson. He holds an MCA and Bsc and from PSG College of Technology in Coimbatore, India, and received his MS in applied statistics from Kennesaw State University.

DR. JOE SUTHERLAND, DIRECTOR, CENTER FOR AI LEARNING, EMORY UNIVERSITY

Joe Sutherland, a noted technology executive, public service leader, and educator, has been named the first Director of the Emory Center for AI Learning, a newly established center that will enable Emory students, faculty and staff to take advantage of AI technologies through training, partnership and co-curricular opportunities, with the goal of catalyzing broad understanding and skill development in AI applications. The Center is integral to the university's AI.Humanity and Student Flourishing strategic initiatives, which will cement Emory as a global leader in the understanding of productive, societally integrated and ethical artificial intelligence innovation.

Joe will foster collaborations with internal executive leadership as well as external partners, working closely with faculty co-leaders Cliff Carrubba, Chair of the Department of Quantitative Theory and Methods in Emory College of Arts and Sciences, and Lance Waller, Professor in the Department of Biostatistics and Bioinformatics in the Rollins School of Public Health.

Dr. Sutherland's professional background includes executive roles at Amazon and academic appointments at Columbia University, Johns Hopkins University, and Emory. He currently serves as Visiting Assistant Professor for QTM, and a fellow of the Weidenbaum Center on the Economy, Government and Public Policy at Washington University in St. Louis. Prior to that role,

he was the director of CX Cloud Data, Insights and Growth at Cisco, where he led applications of artificial intelligence for their CX Cloud product portfolio.

Joe has also founded two startups: Peachtree AI, a professional services firm specializing in artificial intelligence integrations, and Prattle, a fintech company that uses natural language processing to forecast both the Federal Reserve's monetary policy decisions and the performance of publicly traded companies.

From 2011 to 2013, he served in the White House Office of Scheduling and Advance for President Barack Obama, traveling with the President in support of various policy initiatives. His research exploring the utilization of machine learning and AI in congressional policy, political behavior and development economics is published in top peer-reviewed journals, including the American Political Science Review, Political Behavior, and Energy.

Put Patients at the Center of Biotech - 1:30 - 3:00 PM

Ted W. Love, MD, Former President & CEO of Global Blood Therapeutics; 2023-2025 Board Chair, Biotechnology Innovation Organization

Dr. Ted Love is the chair of the Board of Directors at the Biotechnology Innovation Organization (BIO). A long-time BIO Board Member, Dr. Love most recently served as president and chief executive officer of Global Blood Therapeutics (GBT) from June 2014 until October 2023, when the company was acquired by Pfizer. During his tenure at GBT, Dr. Love led the company from a pre-clinical start-up, through the accelerated approval and launch of Oxbryta®, and into a global commercial company with an advanced pipeline of innovative therapies focused on sickle cell disease. Prior to GBT, Dr. Love was executive vice president, research and development and technical operations, at Onyx Pharmaceuticals, Inc., where he played an instrumental role in the accelerated approval of Kyprolis® for multiple myeloma, and the subsequent purchase of Onyx by Amgen. Previously, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., and as senior vice president, development, at Theravance, Inc.

Dr. Love began his biotech career at Genentech in 1992, where he held a number of senior management positions in medical affairs and product development, and ultimately as chairman of Genentech's Product Development Committee. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva® and Avastin®. Prior to Genentech, Dr. Love was a member of the Department of Cardiology at the Massachusetts General Hospital.

Dr. Love currently serves on the boards of directors of Royalty Pharma and Seagen. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.

GREG VAUGHN, MD, SENIOR ADVISOR, GRA; PARTNER, SPENCER STUART

Greg Vaughn, M.D., is a highly-regarded physician executive with over 30 years' experience in healthcare. His clients are senior executives and boards who prioritize attracting and developing extraordinary, high-potential, high-impact leaders. Greg has deep knowledge of the leadership talent pools across healthcare sectors, including healthcare systems and services, proven physician leaders, and board directors. He is known for helping clients ensure their organizations are equitable and inclusive environments able to attract and build diverse, performance-driven leadership teams and boards.

Prior to joining Spencer Stuart, Greg was CEO of Bauerfeind USA, a medical device and sports products company based in Germany. He led the transformation of the U.S. business to a consumer-centric sales and marketing enterprise.

Greg spent several years at Medtronic, a global leader in medical technology solutions and services. He led two "startup" entities, securing FDA clearances and launching two products.

Greg also served as vice president at NDCHealth (now RelayHealth Pharmacy Solutions of McKesson) and was as an engagement manager at McKinsey & Company, serving clients on talent, organization, strategy and operations projects.

Prior to transitioning to management consulting, Greg practiced in both academic and private clinic settings as a board-certified ophthalmologist.

Greg earned a B.A., *summa cum laude*, in history from Emory University and a M.D. from Harvard Medical School. Greg's active civic engagement includes serving on the Emory University Board of Trustees, Woodruff Health Sciences Center Board, Achieve Atlanta Board of Directors, and The Carter Center Board of Trustees.

THE HONORABLE MAYOR JOHN BRADBERRY

John and his wife Christy grew up in Sandy Springs. After college, they settled in the North Fulton area in what would later become Johns Creek. When Johns Creek was incorporated in 2006, John, like many other residents, felt that the new city offered its citizens the kind of protection and local control of policies and expenditures that would benefit the citizens directly.

When John married in 2003, they moved into their house in Johns Creek, where he served as the homeowners association (HOA) president of his neighborhood. Through that HOA role, John became increasingly aware of Johns Creek's challenges and its newly formed government. He began attending City Council meetings and got involved in the Johns Creek Community Association. As a citizen, John started Preserve Johns Creek, a group dedicated to protecting its residential character and quality of life.

Before he was elected Mayor, John served four years as a City Council Member for Post 3. John was elected as Mayor in November 2021. His message for his campaign included three important priorities; Safety First, Building Greater Community, and Forward Together.

John is a graduate of the University of Georgia (UGA) with a BBA in Management Information Systems. He has a landscape design business as well as other business interests, mainly in real estate. John is a former United States Marine and a member of the Johns Creek Veterans Association. He has served on the board of One Johns Creek, a coalition dedicated to helping youth mental health and prevention of substance abuse. Christy attended Auburn University and is a pharmacist. Christy, John, and their daughter Gracie attend Northpoint Community Church.

Launching and Funding a Company in a Challenging Environment: Investors' Perspectives of Best Practices and Critical Errors - 4:00 - 5:15 PM

JUSTIN BURNS, PHD, BIOTECH/HEALTHCARE VENTURE CAPITAL AT MORNINGSIDE

Justin Burns is a member of the investment team at Morningside where he evaluates new opportunities and supports company creation and financing for companies in the life sciences, Ag-Tech, and digital health fields. Additionally, Justin provides operational support and managerial oversight to portfolio companies and serves as a director on the boards of several biotechnology companies, including Pinteon Therapeutics and Prospective Research. Prior to joining Morningside, Justin was a director in the licensing and intellectual property office at Emory University where he negotiated and executed exclusive commercial licenses and institutional research collaborations. Additionally, he held primary responsibility for the university's research, data, and clinical trial contracting. Prior to his tenure at Emory, Justin completed fellowships with the National Academies after receiving his Ph.D. in molecular biology and biochemistry from the Georgia Institute of Technology.

MATT GOLDMAN, PARTNER, J2 VENTURES

Matt is currently a partner with J2 Ventures, a dual-use technology venture capital fund. Previously, he was the Chief Medical Officer and one of the founding members of the Defense Innovation Unit (DIU). At DIU, Matt worked to accelerate the transition of commercial innovation and technology into the hands of our service members across a wide range of topics including human performance, safety, survivability, prevention of combat injuries and training & simulation.

In addition, Matt is a practicing physician at Stanford Children's Health, where he is a Clinical Assistant Professor of Pediatric Gastroenterology. As a researcher, he was part of NATO's personalized medicine and performance sub-committee's, active in developing enteric pathogen vaccines and recently collaborated on projects using wearable technology to help with pre-symptomatic identification of infectious diseases including COVID-19.

JOSHUA ECKELBERRY, PRINCIPAL, SOLAS BIOVENTURES

Joshua Eckelberry graduated with honors from East Tennessee State University with a BS in Biochemistry as a Mayme Frazier Scholar and then attended Quillen College of Medicine for two years on the nationally ranked rural health track before diverting to pursue an MBA in Healthcare Administration. While in school he pioneered Quillen's anatomy lab internship where he helped create the school's first digital dissector, served as president of the local American Medical School Association, helped negotiate a hospital staffing contract worth over \$1M, and raised over \$200K for area non-profit clinics. With his understanding of both the science and business sides of the life science industry, Josh helps translate and negotiate the optimal outcome for patients and the companies. Josh has a lifelong commitment to drive positive impact on the community and the world through leveraged change.

STEVEN LEHMANN, DIRECTOR, VENTURE OPERATIONS, PORTAL INNOVATIONS

Steve Lehmann leads venture investing at Portal. He and his team invest in emerging biotech startups across Chicago, Atlanta, Houston, and Boston. He is a "startup midwife" who has spent the last decade helping inventors turn their discoveries into businesses, whether in a startup, a university, or a refugee camp. At Portal, he invented Stargaze™, an AI system that maps the universe of biotech innovation, predicts where it is headed, and uncovers emerging innovation superstars. Before Portal, he led the George Shultz Innovation Fund at UChicago, where he nucleated and invested in university spinouts. Prior to UChicago he was an Associate for Ocean Tomo's Innovation Management practice, where he advised companies on how to acquire, develop, and commercialize technologies.

MARTA NEW, PHD, MBA, CEO, RADYUS RESEARCH

Dr. Marta New obtained a degree in Immunology and Microbiology from the University of Illinois at Chicago (2006) and completed a postdoctoral fellowship at Northwestern University (2009). She then obtained an MBA in Finance and Marketing at Kellogg School of Management in Chicago (2011). Dr. New has extensive experience in venture capital investments and continues to translate that experience into tangible solutions for clients in need of strategic product development, fundraising, and commercialization of preclinical therapeutics.

Dr. Marta New is the founder and CEO of Radyus Research. As an experienced drug developer with a background in early-stage venture capital, large pharma R&D, and university technology transfer, she brings invaluable business acumen and extensive international connections to Radyus. Dr. New's previous roles as partner at Agent Capital, principal investor at Baxalta Ventures, commercial lead at Baxter International's renal franchise, and entrepreneur in residence at Northwestern University have helped her establish the foundation for the work done at Radyus.

At Agent Capital, Dr. New participated in multiple venture capital investments in oncology, immunology, and rare disease areas, including Pliant Therapeutics (NASDAQ:PLRX), Orchard Therapeutics (NASDAQ:ORTX), and Verge Genomics. At Baxalta Ventures, the corporate venture capital arm of Baxalta in Cambridge, MA, Dr. New participated in multiple venture capital investments and served as a board observer for Gadeta BV, Syntimmune, and Vitesse Biologics (early-stage accelerator funded by Baxalta, Mayo Clinic, and Velocity Pharmaceutical Development). At Northwestern University's technology transfer office, Dr. New served as an entrepreneur in residence and facilitated formation of several biotech spinout companies in the oncology and CNS space.

Dr. New received her PhD in Immunology and Microbiology from the University of Illinois at Chicago and completed a postdoctoral fellowship at Northwestern University. She then earned an MBA in Finance and Marketing at Kellogg School of Management in Chicago.

Dr. New spent most of her career translating early academic research into differentiated therapeutics and draws her expertise from positions at Baxter, Baxalta Ventures, Agent Capital, and Northwestern's technology transfer. Additionally, she has participated in building several successful academic spinouts and invested in over 20 biotech companies.

Poster Session Judges

JAMIE GRAHAM, JD

Jamie Graham is a biotech/chemical patent attorney having over 30 years of patent law experience. Her role is to help clients obtain, investigate, acquire, license, defend against and enforce patents in the life sciences and chemistry technologies in the US and abroad. She obtained an undergraduate degree in Molecular Biology from Wellesley College, a law degree and an Advanced Degree in Immunology from Emory University with research performed at the Centers for Disease Control and Prevention (CDC), is registered to practice before the US Patent and Trademark Office, was a laboratory technician with the Sloan Kettering Institute for Cancer Research, was a research scientist with Boehringer Ingelheim in Ridgefield, CT, was In-house Patent Counsel for CytRx Corporation, a pharmaceutical company in Georgia, and has been an Expert Witness for Boehringer Ingelheim in several patent disputes.

RICHARD A. HILLSTEAD, PH.D., FAHA

Rick Hillstead has been actively involved in the design and development of medical devices for more than thirty years. He held several progressive, Product Research and Development positions with Cordis Corporation (Johnson & Johnson) from 1987 to 1993 where he pioneered device development in the Cordis Coronary Stent program as a Senior Corporate Research Engineer. He then directed new technology development for Novoste Corporation from 1993 until 1999 primarily focusing on intravascular brachytherapy catheters and systems for the treatment of coronary restenosis following angioplasty and stenting. In 1999 he became a founding member of The Innovation Factory, a private medical device incubator in Duluth, GA. He was also a principal partner and founding member in Accuitive Medical Ventures I and II (2004–2007). Accuitive Medical Ventures is a \$225M venture capital fund focusing on medical devices. At The Innovation Factory he served as Chief Science Officer and was primarily responsible for technical due diligence, deal structure and negotiation, early clinical investigations, and overall R&D in a wide variety of Life Science ventures. He has negotiated life science development agreements with academic institutions and individuals in the UK, Australia, and throughout the US. In 2008 he joined Georgia Venture Partners (GVP), Atlanta GA. and remains a partner today. He has managed numerous, diverse, multi-disciplinary development teams from product concept through sales release. He often speaks on the importance of Innovation and Intellectual Property to the entrepreneurial process in the medical device industry at conferences and scientific sessions.

Dr. Hillstead is most recently CEO of Richard A. Hillstead Inc., a medical device development and entrepreneurship consulting firm located in Atlanta, GA. He is also the Chairman and former CEO of Biofisica Inc., He is a past Chairman and co-founder of Cerebral Vascular Applications, Inc. (CVA), a Georgia company dedicated to reducing the incidence of stroke through closure of the atrial appendage of the heart via minimally invasive techniques. Dr. Hillstead currently sits on the Emory University New Technology Advisory Board where he actively participates in reviewing promising new Medical Device Technologies and recommending development strategies.

He is an accomplished inventor named on approximately eighty issued U.S. patents and pending applications and dozens of international patents. He has given expert witness testimony in the field of medical devices in US courts and arbitrations and served as an expert

witness to the High Court of Justice in the UK and multiple cases in Germany and The Netherlands. He has submitted expert declarations and appeared in person in connection with patent oppositions at the European Patent Office. He served as an EIR to the US FDA in 2012 and 2013 and continues to work on innovative projects with the FDA/CDRH Dr. Hillstead is a Fellow in the American Heart Association on the Council of Clinical Cardiology; Fellow on the The Council on Lifestyle and Cardiometabolic Health; and a current member of the Stroke Council and council on Cardiopulmonary Resuscitation.

STACY (WILLIAMS SHUKER) REECE, PHD.

Stacy is the former Director of the Center of Innovation for Life Science where she pioneered the use of social media in economic development. She was also the Director of Partnership Development for Georgia Bio. After a two year stint with an information security startup, she taught herself to screen print and launched the home goods company, Down South House & Home. She and her husband, Chuck Reece, also launched the online magazine, Salvation South, in the fall of 2021. Salvation South commentaries can be heard on Fridays on all Georgia Pubic Broadcasting radio stations. Down South House & Home is relaunching its podcast series in 2024.